Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging StudyAsit Parikh, Brian G. Feagan, Timothy Leach et al.|Inflammatory Bowel Diseases|2011Cited by 211
Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Melmed, Corey A. Siegel, Brian Bressler et al.|Clinical Gastroenterology and Hepatology|2016Cited by 48
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitisCatherine Scholz, Lisa Von Moltke, T. Wyant et al.|Journal of Crohn s and Colitis|2009Cited by 4
Vedolizumab—A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel DiseaseMaria Rosario, Irving H. Fox, Diane R. Mould et al.|Unknown|2019Cited by 1